Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib for platinum-resistant recurrent ovarian cancer
ChiCTR2000038493Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in ovarian cancer, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: progression-free survival. Started Oct 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000038493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038493.